Table 1.
Patient characteristics: Immunohistochemical staining for oestrogen receptors (ER) (ER alpha, ER beta) and progesterone receptors (PR) (PR-A and PR-B) were performed and analysed as previously published by our research group[25]
| Grade (%) | 1 | 147 (51.2) |
|---|---|---|
| (n = 287) |
2 |
93 (32.4) |
| |
3 |
47 (16.4) |
|
FIGO stage (%) |
I |
219 (75.0) |
| (n = 292) |
II |
21 (7.2) |
| |
III |
44 (15.1) |
| |
IV |
8 (2.7) |
|
Histology (%) |
Endometrioid |
212 (72.6) |
| (n = 292) |
Serous |
23 (7.9) |
| |
Clear cell |
5 (1.7) |
| |
Mucinous |
12 (4.1) |
| |
Squamous cell |
1 (0.3) |
| |
Mixed |
34 (11.6) |
| |
Undifferentiated |
5 (1.7) |
|
Patient age ± sem [y] (range) |
|
65.1 ± 0.6 (35.6-88.1) |
|
Deaths (%) |
|
160 (54.8) |
|
Survival ± sem [y] (95% CI) |
|
13.6 ± 0.5 (12.6-14.6) |
|
Follow up ± sem [y] (95% CI) |
|
13.8 ± 0.3 (13.1-14.5) |
|
Glycodelin (%) (n = 291) |
Low |
79 (27.1) |
| |
Intermediate |
152 (52.2) |
| |
High |
60 (20.6) |
|
Glycodelin A (%) (n = 289) |
Low |
82 (28.4) |
| |
Intermediate |
181 (62.6) |
| |
High |
26 (9.0) |
|
ER alpha (%) (n = 292) |
Positive |
133 (45.5) |
|
ER beta (%) (n = 292) |
Positive |
40 (13.7) |
|
PRA (%) (n = 292) |
Positive |
121 (41.4) |
|
PRB (%) (n = 292) |
Positive |
134 (45.9) |
|
Co-morbidities |
Hypertension (%) |
116 (39.7) |
| |
Diabetes (%) |
33 (11.3) |
| |
Obesity (%) |
89 (30.5) |
|
Lymphangiosis (%) (n = 292) |
Positive |
27 (9.2) |
| |
Negative |
263 (90.1) |
| |
Unknown |
2 (0.7) |
|
Hemangiosis (%) (n = 292) |
Positive |
8 (2.7) |
| |
Negative |
281 (96.2) |
| |
Unknown |
3 (1.0) |
|
Radiotherapy (%) (n = 292) |
Yes |
116 (39.7) |
| |
No |
170 (58.2) |
| |
Declined |
6 (2.1) |
|
Chemotherapy (%) (n = 292) |
Yes |
7 (2.4) |
| |
No |
283 (96.9) |
| Declined | 2 (0.7) |